The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESTRO 2026 | One-Stop SABR: same-day sim-plan-and-treat single fraction SABR for early lung cancer
Neil Wallace, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses findings from the One-Stop SABR (ACTRN12624001431516) trial evaluating the feasibility and patient acceptability of same-day sim-plan-and-treat single fraction stereotactic ablative body radiotherapy (SABR) for early lung cancer. Treatment was found to be feasible and acceptable by patients, with positive patient satisfaction reported. Dr Wallace highlighted cross-departmental communication and patient comfort as key aspects which ensured success of the treatment. This interview took place at the European Society for Radiotherapy and Oncology 2026 Congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
